Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

73.92 +0.30 (+0.41%)
Streaming Delayed Price Updated: 11:38 AM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,703
Open 73.53
Bid (Size) 73.90 (2)
Ask (Size) 73.94 (1)
Prev. Close 73.62
Today's Range 72.95 - 74.22
52wk Range 65.07 - 86.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte Corporation
Via Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
From Incyte Corporation
Via Business Wire

Performance

YTD
-7.08%
-7.08%
1 Month
-6.43%
-6.43%
3 Month
-8.28%
-8.28%
6 Month
+7.43%
+7.43%
1 Year
-3.47%
-3.47%

More News

Read More
Why Shares of MacroGenics Climbed Thursday
Via The Motley Fool
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
From Incyte Corporation
Via Business Wire
Analyst Expectations for Incyte's Future
Via Benzinga
Incyte's Return On Capital Employed Overview
Via Benzinga
Which S&P 500 Stocks Look Most Attractive Now?
Via Talk Markets
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
Via Benzinga
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
Analyst Ratings for Incyte
Via Benzinga
Earnings Outlook For Incyte
Via Benzinga
2 Steady Stocks to Buy in a Recession
Via The Motley Fool
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
From Incyte Corporation
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Via Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
Via Benzinga
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
Via Talk Markets
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.